**Question:** Which of the following is active against atypical mycobacteria -

A. Rifampicin
B. Ethambutol
C. Pyrazinamide
D. Amikacin

**Core Concept:** Atypical mycobacteria are non-tuberculous mycobacteria that can cause infections in humans, particularly Mycobacterium avium complex (MAC) and Mycobacterium abscessus. These organisms are resistant to many commonly used antitubercular drugs and require specific treatments.

**Why the Correct Answer is Right:** Among the options provided, Amikacin (D) is active against atypical mycobacteria due to its ability to penetrate macrophages, where atypical mycobacteria predominantly reside. Amikacin is a member of the aminoglycoside class of antibiotics and works by inhibiting bacterial protein synthesis by binding to the 30S ribosomal subunit, leading to bacterial cell death.

**Why Each Wrong Option is Incorrect:**

A. Rifampicin (Rifampin) is an antibiotic primarily used in the treatment of tuberculosis (TB). It works by inhibiting RNA polymerase, which is specific to bacteria, not atypical mycobacteria.

B. Ethambutol (Embedded Butylated Hydroxyanisole) is effective against Mycobacterium tuberculosis but is not active against atypical mycobacteria. It acts by blocking mycolic acid synthesis in the cell wall of mycobacteria, causing cell death.

C. Pyrazinamide (PZA) is a drug used in the initial phase of TB treatment. It works by inhibiting pyrazinoate mono-oxygenase, which is specific to Mycobacterium tuberculosis. It is not effective against atypical mycobacteria.

**Core Concept:** Atypical mycobacteria are distinct from Mycobacterium tuberculosis and require specific treatments due to their unique characteristics and resistance patterns.

**Clinical Pearl:** The treatment of atypical mycobacterial infections involves a combination of antibiotics targeting different cellular processes and mechanisms to ensure a broad spectrum of activity. The correct treatment regimen depends on the specific type of atypical mycobacteria involved, their susceptibility pattern, and the patient's clinical condition. Consultation with a microbiologist or infectious diseases specialist is often necessary for accurate diagnosis and treatment planning.